Prospects for treating osteoarthritis: Enzyme–protein interactions regulating matrix metalloproteinase activity

Therapeutic Advances in Chronic Disease

Volumn 3, Issue 5, 2012, Pages 219-229

  Meszaros, Evan ^a   Malemud, Charles J ^b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Gelatinase; Matrix metalloproteinase; Neutrophil gelatinase associated lipocalin; Osteoarthritis

Indexed keywords

ADALIMUMAB; AGGRECAN; CARRIER PROTEINS AND BINDING PROTEINS; COLLAGEN TYPE 6; COLLAGENASE 3; DECORIN; FIBRONECTIN; GELATINASE A; GELATINASE B; INFLIXIMAB; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; METHOTREXATE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SCLEROPROTEIN; SIDEROCALIN; SYNDECAN 4; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TISSUE INHIBITOR OF METALLOPROTEINASE 4; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

ARTICULAR CARTILAGE; COLLAGEN DEGRADATION; DISEASE COURSE; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME BINDING; ENZYME INHIBITION; ENZYME PROTEIN INTERACTION; ENZYME REGULATION; ENZYME SPECIFICITY; ENZYME SUBSTRATE COMPLEX; GENE EXPRESSION REGULATION; HUMAN; KNEE OSTEOARTHRITIS; MASS SPECTROMETRY; MOLECULAR WEIGHT; NONHUMAN; OSTEOARTHRITIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; REVIEW; RHEUMATOID ARTHRITIS;

EID: 84868630928     PISSN: 20406223     EISSN: 20406231     Source Type: Journal    
DOI: 10.1177/2040622312454157     Document Type: Review

References (95)

1. Abergel R. Clifton M. Pizarro J. Warner J. Shuh D. Strong R. et al. (2008) The siderocalin / enterobactin interaction: a link between mammalian immunity and bacterial iron transport. J Am Chem Soc 130: 11524–11534.
2. Aida Y. Maeno M. Suzuki N. Shiratsuchi H. Motohashi M. Matsumura H. (2005) The effect of IL-1β on the expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in human chondrocytes. Life Sci 77: 3210–3221.
3. Ala-aho R. Kahari V. (2005) Collagenases and cancer. Biochimie 87: 273–286.
4. Alcaraz M. Megías J. García-Arnandis I. Clérigues V. Guillén M. (2010) New molecular targets for the treatment of osteoarthritis. Biochem Pharmacol 80: 13–21.
5. Bergmann U. Tuuttila A. Stetler-Stevenson W. Tryggvason K. (1995) Autolytic activation of recombinant human 72 kilodalton type IV collagenase. Biochemistry 34: 2819–2825.
6. Bolignano D. Donato V. Coppolino G. Campo S. Buemi A. Lacquaniti A. et al. (2008) Neutrophil gelatinase-associated lipocalin (NGAL) as a marker of kidney damage. Am J Kidney Dis 52: 595–605.
7. Borregaard N. Cowland J. (2006) Neutrophil gelatinase-associated lipocalin, a siderophore-binding eukaryotic protein. Biometals 19: 211–215.
8. Brew K. Dinakarpandian D. Nagase H. (2000) Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 1477: 267–283.
9. Brinckerhoff C. Matrisian L. (2002) Matrix metalloproteinases: a tail of the frog that became a prince. Nat Rev Mol Cell Biol 3: 207–214.
10. Burrage P. Brinckerhoff C. (2007) Molecular targets in osteoarthritis: metalloproteinases and their inhibitors. Curr Drug Targets 8: 293–303.
11. Burrage P. Mix K. Brinckerhoff C. (2006) Matrix metalloproteinases: role in arthritis. Front Biosci 11: 529–543.
12. Cernaro V. Bolignano D. Donato V. Lacquaniti A. Buemi A. Crasci E. et al. (2011) NGAL is a precocious marker of therapeutic response. Curr Pharm Des 17: 844–849.
13. Chakraborty S. Kaur S. Guha S. Batra S. (2012) The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer. Biochim Biophys Acta 1826: 129–169.
14. Chevalier X. Goupille P. Beaulieu A. Burch F. Bensen W. Conrozier T. et al. (2009) Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind placebo-controlled trial. Arthritis Rheum 61: 344–352.
15. Clutterbuck A. Asplin K. Harris P. Allaway D. Mobasheri A. (2009) Targeting matrix metalloproteinases in inflammatory conditions. Curr Drug Targets 10: 1245–1254.
16. Cohen S. Proudman S. Kivitz A. Burch F. Donohue J. Burstein D. et al. (2011) A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the knee. Arthritis Res Ther 13: R125.
17. Coles M. Diercks T. Muehlenweg B. Bartsch S. Zölzer V. Tschesche H. (1999) The solution structure and dynamics of human neutrophil gelatinase-associated lipocalin. J Mol Biol 289: 139–157.
18. Correnti C. Strong R. (2012) Mammalian siderophores, siderophore-binding lipocalins and the labile iron pool. J Biol Chem 287: 13524–13531.
19. Curran M. (2010) Hyaluronic acid (Supartz®): a review of its use in osteoarthritis of the knee. Drugs Aging 27: 925–941.
20. Davidson R. Walters J. Kevorkian L. Darrah C. Cooper A. Donell S. et al. (2006) Expression profiling of metalloproteinases and their inhibitors in synovium and cartilage. Arthritis Res Ther 8: R124.
21. Du Z. Yuan H. Wu B. Chang J. Lv Z. Shen J. et al. (2011) Neutrophil gelatinase-associated lipocalin in gastric carcinoma cells and its induction by TPA are controlled by C/EBPβ. Biochem Cell Biol 89: 314–324.
22. Fernandes J. Martel-Pelletier J. Pelletier J. (2002) The role of cytokines in osteoarthritis pathophysiology. Biorheology 39: 237–246.
23. Fernández C. Yan L. Louis G. Yang J. Kutok J. Moses M. (2005) The matrix metalloproteinase-9/neutrophil gelatinase-associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients. Clin Cancer Res 11: 5390–5395.
24. Flower D. (1996) The lipocalin protein family: structure and function. Biochem J 318: 1–14.
25. Freije J. Balbín M. Pendás A. Sánchez L. Puente X. López-Otin C. (2003) Matrix metalloproteinases and tumor progression. Adv Exp Med Biol 532: 91–107.
26. Gege C. Bao B. Bluhm H. Boer J. Gallagher B. Korniski B. et al. (2012) Discovery and evaluation of a non-Zn chelating, selective matrix metalloproteinase 13 (MMP-13) inhibitor for potential intra-articular treatment of osteoarthritis. J Med Chem 55: 709–716.
27. Goetz D. Holmes M. Borregaard N. Bluhm M. Raymond K. Strong R. (2002) The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. Mol Cell 10: 1033–1043.
28. Goetz D. Willie S. Armen R. Bratt T. Borregaard N. Strong R. (2000) Ligand preference inferred from the structure of neutrophil gelatinase associated lipocalin. Biochemistry 39: 1935–1941.
29. Goldring M. Goldring S. (2007) Osteoarthritis. J Cell Physiol 213:626–634.
30. Goldring M. Otero M. Plumb D. Dragomir C. Favero M. El Hachem K. et al. (2011) Roles of inflammatory and anabolic cytokines in cartilage metabolism: signals and multiple effectors converge upon MMP-13 regulation in osteoarthritis. Eur Cell Mater 21: 202–220.
31. Gupta K. Shukla M. Cowland J. Malemud C. Haqqi T. (2007) Neutrophil gelatinase-associated lipocalin (NGAL) is expressed in osteoarthritis and forms a complex with matrix metalloproteinase-9. Arthritis Rheum 56: 3326–3335.
32. Gupta K. Shukla M. Malemud C. Cowland J. Haqqi T. (2006) Neutrophil gelatinase-associated lipocalin (NGAL) is produced by IL-1β-stimulated human osteoarthritis chondrocytes and protects MMP-9 from degradation. Osteoarthritis Cartilage 14(Suppl. B): S87–S88.
33. Hedbom E. Häuselmann H. (2002) Molecular aspects of pathogenesis in osteoarthritis: the role of inflammation. Cell Mol Life Sci 59: 45–53.
34. Hollander A. Pidoux I. Reiner A. Rorabeck C. Bourne R. Poole A. (1995) Damage to type II collagen in aging and osteoarthritis starts at the articular surface, originates around chondrocytes, and extends into the cartilage with progressive degeneration. J Clin Invest 96: 2859–2869.
35. Hulejová H. Baresová V. Klèzl Z. Polanská M. Adam M. Senolt L. (2007) Increased level of cytokines and matrix metalloproteinases in osteoarthritic subchondral bone. Cytokine 38: 151–156.
36. Iannone F. Lapadula G. (2003) The pathophysiology of osteoarthritis. Aging Clin Exp Res 15: 364–372.
37. Jackson M. Smith M. Smith S. Jackson C. Xue M. Little C. (2009) Activation of cartilage matrix metalloproteinases by activated protein C. Arthritis Rheum 60: 780–791.
38. John A. Tuszynski G. (2001) The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res 7: 14–23.
39. Kapoor M. Martel-Pelletier J. Lajeunesse D. Pelletier J-P. Fahmi H. (2011) Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev Rheumatol 7: 33–42.
40. Karlsen J. Borregaard N. Cowland J. (2010) Induction of neutrophil gelatinase-associated lipocalin expression by co-stimulation with interleukin-17 and tumor necrosis factor-α is controlled by IkappaB-ζ but neither by C/EBP-β nor C/EBP-δ. J Biol Chem 285: 14088–14100.
41. Kim K. Choi H. Lee Y. Choi I. Lee S. Hong S. et al. (2011) Expression levels and association of gelatinases MMP-2 and MMP-9 and collagenases MMP-1 and MMP-13 with VEGF in synovial fluid of patients with arthritis. Rheumatol Int 31: 543–547.
42. Kjeldsen L. Bainton D. Sengeløv H. Borregaard N. (1994) Identification of neutrophil gelatinase-associated lipocalin as a novel matrix protein of specific granules in human neutrophils. Blood 83: 799–807.
43. Kjeldsen L. Cowland J. Borregaard N. (2000) Human neutrophil gelatinase-associated lipocalin and homologous proteins in rat and mouse. Biochim Biophys Acta 1482: 272–283.
44. Kjeldsen L. Johnsen A. Sengeløv H. Borregaard N. (1993) Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem 268: 10425–10432.
45. Koskinen A. Vuolteenaho K. Nieminen R. Moilanen T. Moilanen E. (2011) Leptin enhances MMP-1, MMP-3 and MMP-13 production in human osteoarthritic cartilage and correlates with MMP-1 and MMP-3 in synovial fluid from OA patients. Clin Exp Rheumatol 29: 57–64.
46. Kubben F. Sier C. Hawinkels L. Tschesche H. van Duijn W. Zuidwijk K. et al. (2007) Clinical evidence for a protective role of lipocalin-2 against MMP-9 autodegradation and the impact for gastric cancer. Eur J Cancer 43: 1869–1876.
47. Kumagai K. Shirabe S. Miyata N. Murata M. Yamauchi A. Kataoka Y. et al. (2010) Sodium pentosan polysulfate resulted in cartilage improvement in knee osteoarthritis–an open clinical trial. BMC Clin Pharmacol 10: 7.
48. Kuriya B. Arkema E. Bykerk V. Keystone E. (2010) Efficacy of initial methotrexate monotherapy versus combination therapy with a biological agent in early rheumatoid arthritis: a meta-analysis of clinical and radiographic emission. Ann Rheum Dis 69: 1298–1304.
49. Lee E. Murphy G. el-Alfy M. Davoli M. Lamplugh L. Docherty A. et al. (1999) Active gelatinase B is identified by histozymography in the cartilage resorption sites of developing long bones. Dev Dyn 215: 190–205.
50. Le Graverand-Gastineau M. (2010) Disease modifying osteoarthritis drugs: facing development challenges and choosing molecular targets. Curr Drug Targets 11: 528–535.
51. Li C. Chan Y. (2011) Lipocalin 2 regulation and its complex role in inflammation and cancer. Cytokine 56: 435–441.
52. Li N. Shi Z. Tang Y. Wang Z. Song S. Qian L. et al. (2011) New hope for the treatment of osteoarthritis through selective inhibition of MMP-13. Curr Med Chem 18: 977–1001.
53. Lochter A. Sternlicht M. Werb Z. Bissell M. (1998) The significance of matrix metalloproteinases during early stages of tumor progression. Ann N Y Acad Sci 857: 180–193.
54. Lorenz H. Richter W. (2006) Osteoarthritis: cellular and molecular changes in degenerating cartilage. Prog Histochem Cytochem 40: 135–163.
55. Mahmoud R. El-Ansary A. El-Eishi H. Kamal H. El-Saeed N. (2005) Matrix metalloproteinases MMP-3 and MMP-1 levels in sera and synovial fluid of patients with rheumatoid arthritis and osteoarthritis. Ital J Biochem 54: 248–257.
56. Malemud C. (2004) Protein kinases in chondrocyte signaling and osteoarthritis. Clin Orthop Relat Res 427(Suppl.): S145–S151.
57. Malemud C. (2006) Matrix metalloproteinases: role in skeletal development and growth plate disorders. Front Biosci 11: 1702–1715.
58. Malemud C. (2007 a) MAP kinases. In: Ed. Buckwalter J. Lotz M. Stoltz J. (eds), OA, Inflammation and Degradation: A Continuum. Biomedical and Health Research, Vol 70. Amsterdam, IOS Press, 99–117.
59. Malemud C. (2007 b) Gene therapy for arthritis: defining novel gene targets. Gene Ther Mol Biol 11: 27–36.
60. Malemud C. (2009 a) The discovery of novel experimental therapies for inflammatory arthritis. Mediators Inflamm 2009: 698769.
61. Malemud C. (2009 b) Recent advances in neutralizing the IL-6 pathway in arthritis. Open Access Rheumatol Res Rev 1: 133–150.
62. Malemud C. (2010) Anticytokine therapy for osteoarthritis: evidence to date. Drugs Aging 27: 95–115.
63. Malemud C. (2011 a) Gene therapy outcomes in experimental models of inflammatory arthritis. In: Ed. Kang C. (ed), Gene Therapy Applications. InTech: Vienna, 189–200.
64. Malemud C. (2011 b) Dysfunctional immune-mediated inflammation in rheumatoid arthritis dictates that development of anti-rheumatic disease drugs target multiple intracellular signaling pathways. Anti-Inflammation Anti-Allergy Agents Med Chem 10: 78–84.
65. Malemud C. Islam N. Haqqi T. (2003) Pathophysiological mechanisms in osteoarthritis lead to novel therapeutic strategies. Cells Tissues Organs 174: 34–48.
66. Malemud C. Pearlman E. (2009) Targeting JAK / STAT signaling pathway in inflammatory diseases. Curr Signal Transduct Ther 4: 201–221.
67. Malemud C. Schulte M. (2008) Is there a final common pathway for arthritis? Future Rheumatol 3: 253–268.
68. Mastbergen S. Lafeber F. (2011) Changes in subchondral bone early in the development of osteoarthritis. Arthritis Rheum 63: 2561–2563.
69. Masure S. Nys G. Fiten P. van Damme J. Opdenakker G. (1993) Mouse gelatinase B, cDNA cloning, regulation of expression and glycosylation in WEHI-3 macrophages and gene organisation. Eur J Biochem 218: 129–141.
70. Matthews G. Hunter D. (2011) Emerging drugs for osteoarthritis. Expert Opin Emerg Drugs 16: 479–491.
71. Miao D. Bai X. Panda D. Karaplis A. Goltzman D. McKee M. (2004) Cartilage abnormalities are associated with abnormal Phex expression and with altered matrix protein and MMP-9 localization in Hyp mice. Bone 34: 638–647.
72. Miyamoto T. Askaka R. Suzuki A. Takatsu A. Kashima H. Shiozawa T. (2011) Immunohistochemical detection of a specific receptor (solute carrier family 22 member 17, SLC22A17) and its prognostic significance in endometrial cancer. Exp Mol Pathol 91: 563–568.
73. Moore C. Crocker S. (2012) An alternate perspective on the role of TIMPS and MMPs in pathology. Am J Pathol 180: 12–16.
74. Piecha D. Weik J. Kheil H. Becher G. Timmermann A. Jaworski A. et al. (2010) Novel selective MMP-13 inhibitors reduce collagen degradation in bovine articular and human osteoarthritis cartilage explants. Inflamm Res 59: 379–389.
75. Praul C. Ford B. Gay C. Pines M. Leach R. (2000) Gene expression and tibial dyschondroplasia. Poult Sci 79: 1009–1013.
76. Provatopoulou X. Gounaris A. Kalogera E. Zagouri F. Flessas J. Goussetis E. et al. (2009) Circulating levels of matrix metalloproteinase-9 (MMP-9), neutrophil gelatinase-associated lipocalin (NGAL) and their complex MMP-9/NGAL in breast cancer disease. BMC Cancer 9: 390.
77. Qoronfleh M. Chowdhury S. Eshraghi J. Ho T. Brake P. Banks T. et al. (1997) Identification of new autolytic sites of recombinant mature human fibroblast stromelysin by mass spectroscopy. J Pept Res 49: 612–619.
78. Sandell L. Aigner T. (2001) Articular cartilage and changes in arthritis. An introduction: cell biology of osteoarthritis. Arthritis Res 3: 107–113.
79. Sandy J. (2006) A contentious issue finds some clarity: on the independent and complementary roles of aggrecanase activity and MMP activity in human joint aggrecanolysis. Osteoarthritis Cartilage 14: 95–100.
80. Schmidt-Ott K. Mori K. Li J. Kalandadze A. Cohen D. Devarajan P. et al. (2007) Dual action of neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol 18: 407–413.
81. Schroeppel J. Crist J. Anderson H. Wang J. (2011) Molecular regulation of articular chondrocyte function and its significance in osteoarthritis. Histol Histopathol 26: 377–394.
82. Schwab W. Schulze-Tanzil G. Mobasheri A. Dressler J. Kotzsch M. Shakibaei M. (2004) Interleukin-1β-induced expression of urokinase-type plasminogen activator receptor and its co-localization with MMPs in human articular chondrocytes. Histol Histopathol 19: 105–112.
83. Shimizu M. Higuchi H. Takagishi K. Shinozaki T. Kobayashi T. (2010) Clinical and biochemical characteristics after intra-articular injection for the treatment of osteoarthritis of the knee: prospective randomized study of sodium hyaluronate and corticosteroid. J Orthop Sci 15: 51–56.
84. Strauss E. Hart J. Miller M. Altman R. Rosen J. (2009) Hyaluronic acid viscosupplementation and osteoarthritis: current uses and future directions. Am J Sports Med 37: 1636–1644.
85. Struglics A. Larsson S. Pratta M. Kumar S. Lark M. Lohmander L. (2006) Human osteoarthritis synovial fluid and joint cartilage contain both aggrecanase- and matrix metalloproteinase-generated aggrecan fragments. Osteoarthritis Cartilage 14: 101–113.
86. Tchetverikov I. Lohmander L. Verzijl N. Huizinga T. TeKoppele J. Hanemaaijer R. et al. (2005) MMP protein and activity levels in synovial fluid from patients with joint injury, inflammatory arthritis, and osteoarthritis. Ann Rheum Dis 64: 694–698.
87. van den Berg W. (2011) Osteoarthritis year 2010 in review: pathomechanisms. Osteoarthritis Cartilage 19: 338–341.
88. Waddell D. Kolomytkin O. Dunn S. Marino A. (2007) Hyaluronan suppresses IL-1[beta]-induced metalloproteinase activity from synovial fluid. Clin Orthop Relat Res 465: 241–248.
89. Wang M. Shen J. Jin H. Im H.J. Sandy J. Chen D. (2011 a) Recent progress in understanding molecular mechanisms of cartilage degeneration during osteoarthritis. Ann N Y Acad Sci 1240:61–69.
90. Wang Y. Hall S. Hanna F. Wluka A. Grant G. Marks P. et al. (2011 b) Effects of Hylan G-F 20 supplementation on cartilage preservation detected by magnetic resonance imaging in osteoarthritis of the knee: a two-year single-blind clinical trial. BMC Musculoskelet Disord 12: 195.
91. Wang X. Li K. Adams E. van Schepdael A. (2011 c) Matrix metalloproteinase inhibitors: a review on bioanalytical methods, pharmacokinetics and metabolism. Curr Drug Metab 12: 395–410.
92. Wisler B. Dennis J. Malemud C. (2011) New organ-specific pharmacological strategies interfering with signaling pathways in inflammatory disorders / autoimmune disorders. Curr Signal Transduct Ther 6: 279–291.
93. Yan L. Borregaard N. Kjeldsen L. Moses M. (2001) The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J Biol Chem 276: 37258–37265.
94. Yang J. Moses M. (2009) Lipocalin 2: a multifaceted modulator of human cancer. Cell Cycle 8: 2347–2352.
95. Zhang L. Yang M. Yang D. Cavey G. Davidson P. Gibson G. (2010) Molecular interactions of MMP-13 C-terminal domain with chondrocyte proteins. Connect Tissue Res 51: 230–239.